Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.22 -2.28 (-3.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
66 67 Next >
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
2 Top Biotech Stocks to Buy Right Now
These two companies each pay market-beating dividends to shareholders. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook
The company's outlook for 2023 profit topped forecasts by 11 cents at the midpoint. 
Via Investor's Business Daily
A Preview Of Bristol-Myers Squibb's Earnings
Via Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
2 Top Biotech Stocks to Buy in February
Biotech stocks aren't all created equal -- these two are the best of the bunch. 
Via The Motley Fool
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
Via Benzinga
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union. 
Via The Motley Fool
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
Life sciences companies may be more immune to work-from-home shifts. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Bristol Myers Squibb Q4 Earnings And Revenues Surpass Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.82 per share. 
Via Talk Markets
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range
Via Benzinga
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For February 01
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock. 
Via The Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
2 Top Dividend Stocks to Buy in 2023 and Hold Forever
These companies are established leaders in their respective fields. 
Via The Motley Fool
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
From Bristol Myers Squibb
Via Business Wire
3 Buffett-Type Stocks to Buy Right Now
These stocks are good value buys for the long haul. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS